Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,769 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Newport Beach, CaliforniaAges 18 years+ - NCT07213609RecruitingPhase 1/Phase 2
Study of GSK5460025 for advanced solid tumors
This trial tests a new drug, GSK5460025, alone or with other cancer treatments, for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help those whose cancer has a specific genetic feature (dMMR or MSI-H) or who have not responded to standard treatments.
Aurora, ColoradoAges 18 years+ - NCT07213570RecruitingPhase 2
Second-line regorafenib for advanced RAS-mutant colorectal cancer
This trial tests regorafenib as a second-line treatment for people with advanced colorectal cancer that has a RAS mutation. It aims to see if this targeted therapy can help when the first treatment stopped working.
Naples, ItalyAges 18 years+ - NCT03592472RecruitingPhase 3
Testing pazopanib with or without abexinostat for kidney cancer
This Phase 3 trial studies how well pazopanib works, and whether adding abexinostat can improve outcomes, for advanced kidney cancer that cannot be removed by surgery or has spread. You may qualify if you have clear cell renal cell carcinoma and have not already had certain targeted kidney-cancer medicines.
Phoenix, ArizonaAges 18 years+ - NCT07208149RecruitingPhase 1/Phase 2
Study of MR001 for advanced triple-negative breast cancer
This trial tests a new drug, MR001, for people with triple-negative breast cancer that has come back or spread. It's for those who've already tried at least one type of treatment.
BeijingAges 18–75 - NCT07204574RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer after first treatment
This trial tests a new drug combination for advanced colorectal cancer that has not gotten better with standard chemotherapy. It is for people whose tumors have normal RAS and BRAF genes, and it adds a new type of medicine (HCB101) to a common chemotherapy plus targeted therapy regimen.
TaoyuanAges 18 years+ - NCT07197580RecruitingPhase 3
Study of a targeted radiation therapy for advanced kidney cancer
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Sydney, New South WalesAges 18 years+ - NCT06940102Recruiting
A study on megestrol acetate for weight loss in advanced digestive cancer
This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).
Shenyang, LiaoningAges 18 years+ - NCT07192432RecruitingPhase 1/Phase 2
Gene therapy for HER2-positive cancer
This trial tests a new gene therapy for people with HER2-positive cancer. It is for two groups: those with advanced cancer that has worsened after treatment, and those with early-stage cancer at high risk of coming back. The goal is to see if the therapy can safely help shrink tumors or prevent return.
Los Angeles, CaliforniaAges 18 years+ - NCT07192068RecruitingPhase 2
Zanidatamab for HER2-altered solid tumors
This trial tests a drug called zanidatamab in people with certain cancers (endometrial, colorectal, head & neck, non-small cell lung, or sarcoma) that have a specific change in the HER2 gene. It's for those whose cancer has spread or can't be removed and who have tried at least one prior treatment.
AngersAges 18 years+ - NCT07174453RecruitingPhase 3
Comparing side effects of different doses of immunotherapy
This study compares standard dosing schedules of pembrolizumab or nivolumab (two immunotherapy drugs) to see which one causes fewer immune-related side effects. It is for people with solid tumors who are already eligible to receive one of these drugs as part of their standard care.
Westwood, KansasAges 18 years+ - NCT07178795RecruitingPhase 3
New drug vs standard care for HER2-mutant lung cancer
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT07166185Recruiting
Targeted therapy before surgery for HER2+ breast cancer
This trial tests a combination of two targeted drugs (trastuzumab and pertuzumab) given as a shot under the skin before surgery for women with a specific type of breast cancer called HER2-positive. The goal is to see if this treatment works well for women in Algeria.
BlidaAges 19 years+ - NCT07172386RecruitingPhase 2
Pre-surgery treatment for advanced kidney cancer
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07162480RecruitingPhase 2
Investigational Drug for Advanced Salivary Gland Cancer (Adenoid Cystic Carcinoma)
This clinical trial studies an experimental drug called AZD8205 for people with a specific type of advanced adenoid cystic carcinoma (ACC). ACC is a rare cancer that usually starts in the salivary glands. The trial aims to see if the drug can shrink tumors or slow the disease, and it's for those whose cancer has spread or come back and fits certain molecular features.
Houston, TexasAges 18 years+ - NCT07155187RecruitingPhase 2/Phase 3
Study of telisotuzumab adizutecan for EGFR-mutated lung cancer
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
Springdale, ArkansasAges 18 years+ - NCT07145450RecruitingPhase 1/Phase 2
T-cell therapy for advanced pancreatic cancer with KRAS mutations
This trial tests a personalized T-cell therapy designed to target pancreatic cancer cells that have a specific KRAS mutation (G12V or G12D). It is for people whose cancer has spread or is locally advanced and who have already benefited from standard treatments.
CopenhagenAges 18 years+ - NCT07154290RecruitingPhase 2
Ubamatamab with or without REGN7075 for advanced lung cancer
This trial tests a new targeted therapy (ubamatamab) alone or with another drug (REGN7075) for people with advanced or metastatic non-small cell lung cancer that has gotten worse after standard treatment. It aims to see if targeting MUC16, a substance found on some cancer cells, can help control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07152405RecruitingPhase 3
New drug vs. chemo for HER2+ stomach cancer
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that has spread. The goal is to see if BL-M07D1 works better than standard chemo.
Harbin, HeilongjiangAges 18–75 - NCT07153887RecruitingPhase 2
Vebreltinib for advanced clear cell sarcoma
This trial tests the drug vebreltinib for people with advanced or spreading clear cell sarcoma. The goal is to see if it can shrink tumors and help patients live longer.
Hangzhou, ZhejiangAges 12 years+ - NCT07149649RecruitingPhase 2/Phase 3
Magnesium for advanced lung cancer
This trial tests if adding magnesium supplements to standard first-line treatment (chemotherapy plus immunotherapy) improves outcomes for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. It is for patients who have not had prior treatment for metastatic disease.
AarauAges 18 years+ - NCT06742411RecruitingPhase 1/Phase 2
Chemo plus immunotherapy and hyperbaric oxygen for advanced stomach cancer
This trial tests a combination of chemotherapy (XELOX), an immunotherapy drug (Sintilimab), and hyperbaric oxygen therapy for people with advanced or metastatic stomach or gastroesophageal junction cancer. The goal is to see if this triple therapy helps shrink or control the cancer better than current options.
Chengdu, SichuanAges 18–75 - NCT07142226Recruiting
Liquid biopsy for advanced bile duct cancer
This trial uses a blood test called ctDNA to look at the genetic makeup of your cancer. It aims to learn more about bile duct cancer and may help guide your treatment choices.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT05631249RecruitingPhase 2
Sotorasib for KRAS G12C lung cancer after prior treatments
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
LyonAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,769 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.